OBJECTIVES:  Persistent erythema associated with rosacea has considerable psychological and social impacts that are important to assess when evaluating treatment efficacy. Two phase 3 pivotal trials examined efficacy and safety of oxymetazoline for treatment of moderate to severe persistent facial erythema associated with rosacea. This report describes Impact Assessment for Rosacea Facial Redness (IA-RFR) outcomes from both trials. METHODS:  In 2 identically designed trials (REVEAL 1 and 2), eligible patients were randomized 1:1 to vehicle or oxymetazoline hydrochloride cream 1.0% (oxymetazoline) applied to the face (QD, 29 days). The impact of erythema associated with rosacea was evaluated using the 8-item IA-RFR, a validated, patient-rated scale. Each item was rated on a 5-point scale (0–4; higher scores indicate more negative impact). Patients completed the IA-RFR at baseline and at hour 6 on follow-up days 1, 15, and 29. Differences between oxymetazoline-group and vehicle-group changes from baseline in IA-RFR total score and Self-perception, Emotional functioning, personal Grooming, and Social functioning domain scores were compared using the van Elteren test. Analyses of item-level changes are ongoing. RESULTS:  IA-RFR assessments included 440 patients in REVEAL 1 (oxymetazoline, n=222; vehicle, n=218) and 443 patients in REVEAL 2 (oxymetazoline, n=223; vehicle, n=220). In REVEAL 1, median change from baseline to day 29 was significantly greater with oxymetazoline vs vehicle for total IA-RFR (−0.60 vs −0.50; P=0.045), personal Grooming (−0.50 vs 0.00; P=0.021), and 1 Self-perception item (self-consciousness; −1.0 vs −1.0; P=0.024). In REVEAL 2, median change from baseline to day 29 was numerically greater for oxymetazoline vs vehicle for the total IA-RFR score (−0.70 vs −0.60). Pooled data analyses are forthcoming. CONCLUSIONS:  Patients with moderate to severe persistent facial erythema associated with rosacea reported greater improvements in impacts of rosacea facial redness when treated with oxymetazoline compared with patients who received vehicle.